logo-loader
viewCanntab Therapeutics Ltd

Canntab Therapeutics teams up with orthopedic surgeon for cannabis tablet trial

A placebo-controlled study led by Dr Don Garbuz will test the effectiveness of the company’s Canntab product in reducing the need for opioids after knee-replacement surgery

A greenhouse with marijuana plants
Canntab plans to create tablets for the study with Toronto-based FSD Pharma

Canntab Therapeutics Ltd (CSE:PILL) (OTCMKTS:TLFTF) said Wednesday that it is teaming up with Dr Don Garbuz, an orthopedic surgeon, to study the effectiveness of the company’s Canntab tablets in reducing the need for opioids after knee-replacement surgery.

The Toronto-based company said in a press release that it’s seeking approval from the university to conduct a randomized, double-blind, placebo-controlled clinical trial, with Garbuz as lead investigator.

READ: Canntab Therapeutics wants to grow awareness of the cannabis group in Canada and elsewhere

Shares of Canntab climbed C$0.07 to C$1.12 in Wednesday's Canadian trading.

Garbuz is head of the division of lower limb reconstruction and oncology at the University of British Columbia’s division of orthopedics.

Canntab plans to create the tablets for the study with Toronto-based FSD Pharma Inc (OTCMKTS:FSDDF), a licensed producer under the Access to Cannabis for Medical Purposes Regulations.

“This study will help advance our understanding of the potential effects of cannabis as a treatment for pain and will become the basis for conducting future cannabinoid and pain management clinical trials," Garbuz said in a statement. "This important study aims to help us better understand the potential impact of cannabis as an alternative for opioids, so that patients might face better outcomes."

It’s not unusual for patients to misuse opioids after surgery, with nearly 5% of “previously opiate-naive patients” becoming chronic abusers, Canntab said in the press release.

The total cost of the study is estimated at C$600,000, with an anticipated time frame of 12 to 18 months.

 

Contact Dennis Fitzgerald at [email protected]

Quick facts: Canntab Therapeutics Ltd

Price: 1.1 CAD

CSE:PILL
Market: CSE
Market Cap: $34.61 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Canntab Therapeutics Ltd named herein, including the promotion by the Company of Canntab Therapeutics Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Canntab Therapeutics gets first commercial sale with Medipharm

Canntab Therapeutics (CSE: PILL- OTCQB: CTABF) CFO Richard Goldstein and Special Advisor Larry Latowsky joined Steve Darling from Proactive Vancouver with news the company has signed their first contract for their slow release tablets with MediPharm.  Goldstein discusses how the...

1 day, 16 hours ago

2 min read